Common pathogenic mechanisms and pathways in the development of COPD and lung cancer
IA Yang, V Relan, CM Wright… - Expert opinion on …, 2011 - Taylor & Francis
Introduction: Lung cancer and COPD commonly coexist in smokers, and the presence of
COPD increases the risk of developing lung cancer. In addition to smoking cessation and …
COPD increases the risk of developing lung cancer. In addition to smoking cessation and …
[PDF][PDF] Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors
Y Lin, X Jiang, Y Shen, M Li, H Ma… - Endocrine-related …, 2009 - researchgate.net
Genetic alterations in the PIK3CA gene of the phosphoinositide 3-kinase (PI3K)/AKT
pathway have been found in many human tumors, but they have not been explored in …
pathway have been found in many human tumors, but they have not been explored in …
Pulmonary adenocarcinoma: a renewed entity in 2011
H Kadara, M Kabbout, II Wistuba - Respirology, 2012 - Wiley Online Library
Lung cancer, of which non‐small‐cell lung cancer comprises the majority, is the leading
cause of cancer‐related deaths in the United States and worldwide. Lung adenocarcinomas …
cause of cancer‐related deaths in the United States and worldwide. Lung adenocarcinomas …
[HTML][HTML] Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers
Introduction: Epidermal growth factor receptor (EGFR) signaling pathway plays a crucial role
in the development and progression of lung cancer. We searched for mutations of EGFR …
in the development and progression of lung cancer. We searched for mutations of EGFR …
Expression signatures in lung cancer reveal a profile for EGFR‐mutant tumours and identify selective PIK3CA overexpression by gene amplification
B Angulo, A Suarez‐Gauthier… - The Journal of …, 2008 - Wiley Online Library
The development of targeted therapies creates a need to discriminate tumours accurately by
their histological and genetic characteristics. Here, we aim to identify gene expression …
their histological and genetic characteristics. Here, we aim to identify gene expression …
[HTML][HTML] Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer
CQ Zhu, JC Cutz, N Liu, D Lau, FA Shepherd… - British journal of …, 2006 - nature.com
Telomerase reactivation is a hallmark of human carcinogenesis. Increased telomerase
activity may result from gene amplification and/or overexpression. This study evaluates the …
activity may result from gene amplification and/or overexpression. This study evaluates the …
Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis
Lung squamous cell carcinoma (SCC) is thought to arise from premalignant lesions in the
airway epithelium; therefore, studying these lesions is critical for understanding lung …
airway epithelium; therefore, studying these lesions is critical for understanding lung …
[HTML][HTML] Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC)
M Ji, H Guan, C Gao, B Shi, P Hou - BMC cancer, 2011 - Springer
Background Lung cancer is the leading cause of cancer-related death worldwide. Genetic
and epigenetic alterations have been identified frequently in lung cancer, such as promoter …
and epigenetic alterations have been identified frequently in lung cancer, such as promoter …
PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress
P Wu, YZ Hu - Current medicinal chemistry, 2010 - ingentaconnect.com
The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also known as
protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital …
protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital …
Current concepts on the molecular pathology of non-small cell lung carcinoma
J Fujimoto, II Wistuba - Seminars in diagnostic pathology, 2014 - Elsevier
Recent advances in the understanding of the complex biology of non-small cell lung
carcinoma (NSCLC), particularly activation of oncogenes by mutation, translocation and …
carcinoma (NSCLC), particularly activation of oncogenes by mutation, translocation and …